PI3K Inhibitors for HR+ Breast Cancer

Evolving Landscape of HR-Positive Metastatic Breast Cancer: A Year in ReviewПодробнее

Module 2 - Treatment of HR+ and HER2- Metastatic Breast Cancer with PI3K and CDK 4/6 InhibitorsПодробнее

PIQRAY® (alpelisib) Mechanism of Action | PIK3CA Mutation in Metastatic Breast CancerПодробнее

PI3K Inhibitors Data Review: How Do They CompareПодробнее

Cancer as a Metabolic Disease: The Role of Food and BeyondПодробнее

2022 West Oncology Conference | Precision Oncology in HR+ Breast CancerПодробнее

Development of PI3K inhibitors by Jasmine FloresПодробнее

PI3K inhibitors for the treatment of brain metastases in HER2-negative breast cancerПодробнее

Targeting Advanced Triple-Negative Breast Cancer | Dana-Farber Cancer InstituteПодробнее

PI3K Inhibitors for HR+ Metastatic Breast CancerПодробнее

Boxer Lecture 2015, Lewis C. Cantley, PhD - PI 3-Kinase and Cancer MetabolismПодробнее

Dr Lewis Cantley speaks at Canada Gairdner Awardees LectureПодробнее

Role of PI3K Inhibitors in HR+ Metastatic Breast CancerПодробнее

Module 1 - Treatment of HR+ and HER2- Metastatic Breast Cancer with PI3K and CDK 4/6 InhibitorsПодробнее

PI3K Inhibitors in HR+ Metastatic Breast CancerПодробнее